discontinuation of development of BI 1467335 for NASH
Boehringer Ingelheim discontinues development of BI 1467335 for NASHBI 1467335 was part of Boehringer Ingelheim ’s growing NASH R&D pipeline portfolio Study of BI 1467335 in diabetic retinopathy will be continued
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news